Saw Palmetto Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

Comparison of 2 Extracts of Saw Palmetto Versus Placebo on BPH Symptoms
Conditions: Benign Prostatic Hyperplasia Interventions: Drug: Saw palmetto extract 320mg per day; Drug: Commercial Saw palmetto extract 320mg per day; Drug: Palm Oil capsule Sponsors: RDC Clinical Pty Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials

Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Condition:   Benign Prostatic Hyperplasia (BPH)Interventions:   Drug: Permixon® 160 mg;   Drug: Tamsulosine Arrow LP;   Drug: Placebo matching Permixon® 160 mg;   Drug: Placebo matching Tamsulosine Arrow LPSponsors:   Pierre Fabre Medicament;   Pierre Fabre MedicamentRecruiting - verified March 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 22, 2012 Category: Research Source Type: clinical trials

Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Condition:   Benign Prostatic Hyperplasia (BPH)Interventions:   Drug: Permixon® 160 mg;   Drug: Tamsulosine Arrow LP;   Drug: Placebo matching Permixon® 160 mg;   Drug: Placebo matching Tamsulosine Arrow LPSponsor:   Pierre Fabre MedicamentCompleted - verified July 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 22, 2012 Category: Research Source Type: clinical trials